19 November 2024 - Talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged.

In the talks both ourselves and NHS England continued to offer as much flexibility as possible, but despite the intervention of Secretary of State for Health Wes Streeting, the companies did not put forward a cost effective price that would have enabled us to recommend Enhertu as value for money for the taxpayer.

Read NICE press release